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Abstract
Background Heterozygous mutations in melanocortin-4
receptor (MC4R) are the most frequent genetic cause of
obesity. Bariatric surgery is a successful treatment for
severe obesity. The mechanisms of weight loss after
bariatric surgery are not well understood.
Methods Ninety-two patients who had Roux-en-Y gastric
bypass (RYGB) surgery were screened for MC4R mutations.
We compared percent excess weight loss (%EWL) in the four
MC4R mutation carriers with that of two control groups:
8 matched controls and with the remaining 80 patients who
underwent RYGB.
Results Four patients were heterozygous for functionally
significant MC4R mutations. In patients with MC4R
mutations, the %EWL after RYGB (66% EWL) was not
significantly different compared to matched controls (70%
EWL) and non-matched controls (60% EWL) after 1 year
of follow-up.
Conclusions This study suggests that patients with hetero-
zygous MC4R mutations also benefit from RYGB and that
weight loss may be independent of the presence of such
mutations.
Keywords Melanocortin-4 receptor.Roux-en-Y gastric
bypass.Obesity
Introduction
Lifestyle modification, such as diet and exercise, is not
effective in maintaining long-term weight loss in patients
with class III (BMI>40 kg/m
2) obesity. Bariatric surgery is
currently the most effective therapy for these patients.
Outcomes after different types of bariatric surgery are
variable and the mechanisms of resultant weight loss are
poorly understood [1]. It has been suggested that the
outcome of these procedures could be influenced by genetic
variations implicated in the predisposition to obesity [2].
Genetic factors account for 40% to 70% of an individual’s
predisposition to obesity [3]. Several known obesity-
associated mutations involve genes of the hypothalamic
leptin–melanocortin system. These include mutations in
leptin, the leptin receptor, proopiomelanocortin, prohormone
convertase 1/3, and melanocortin-4 receptor (MC4R) [3–5].
Specifically, heterozygous MC4R mutations are the most
common genetic form of obesity, and mutations in this
gene account for approximately 2.5% of severely obese
individuals [6, 7].
MC4R is expressed at low levels and is found in
hypothalamic nuclei involved in the regulation of food
intake and in particular neurons of the paraventricular
nucleus [8]. The physiological role of MC4R in food intake
and body weight regulation is best demonstrated by the
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DOI 10.1007/s11695-010-0295-8phenotype of the MC4R knockout mice [9]. Mice lacking
both alleles of MC4R (MC4R
−/− mice) develop a maturity-
onset hyperphagic obesity syndrome by 10 weeks of age.
Mice heterozygous for an MC4R deletion (MC4R
+/− mice)
show an average weight that is intermediate between that of
wild-type and MC4R
−/− mice. This suggests that haplo-
insufficiency at the MC4R locus is sufficient to cause an
alteration in the regulation of body weight in rodents.
MC4R regulates food intake and maintains long-term
energy homeostasis by integrating signals provided by its
agonist α-melanocyte stimulating hormone and antagonist
agouti-related peptide from leptin-sensitive neurons in the
arcuate nucleus [10]. An important argument for showing
that non-synonymous mutations are responsible for a
disease is the demonstration of the functional relevance of
these mutations (i.e., the demonstration that the mutated
product behaves differently in a functional assay). Func-
tional studies of MC4R mutations associated with obesity
indicate that multiple functional alterations contribute to
their pathogenicity and that more severely impaired
receptor function in vitro correlates with earlier age of
obesity onset and higher BMI [6].
Lifestyle interventions based on exercise, behavior, and
nutrition therapy in children with MC4R mutations are not
effective in providing long-term weight loss in contrast to
children without MC4R mutations [11]. In addition, a
controversial report suggested that carriers of non-obesity-
associated genetic variations at the MC4R locus might
have poorer weight loss outcomes after gastric banding
[2, 12].
Here,wecompare the weight loss outcome after Roux-
en-Y gastric bypass (RYGB) in patients who are heterozy-
gous carriers of rare functionally relevant obesity-associated
MC4R mutations with that of control patients who do not
carry such mutations.
Patients and Methods
Patients
Ninety-two patients who were considered appropriate
candidates for RYGB were screened for MC4R mutations.
Criteria used at the University of California San Francisco
Bariatric Surgery Program for the selection of patients for a
RYGB has been described in detail previously [13]. Briefly,
all patients met the 1991 NIH Consensus Development
Conference guidelines, including: BMI (weight in kilo-
grams divided by height in meters squared) >40 or BMI
between 35 and 40 with obesity-related comorbidities for at
least 5 years and a documented attempt of medically
supervised therapy for weight loss for at least 6 months
[14]. All patients also underwent preoperative psycholog-
ical, nutritional, and medical evaluations. Active binge
eating disorder is considered a contraindication for bariatric
surgery at the UCSF Bariatric Program. Procedure selection
was determined by patient preference and occurred after
participation in a 1-h educational and screening session
with a dietician and a bariatric surgeon and after medical
and psychological clearances.
Surgical Technique for RYGB
The technique for RYGB has been described previously
[15]. In brief, it was performed laparoscopically using
staplers (US Surgical Corporation, Norwalk, CT) to create
a 15- to 30-mL gastric pouch, the antecolic gastro-
jejunostomy, the100-cm Roux limb, and the side-to-side
jejunojejunostomy.
Postoperative Care
Patients were given clear liquids on the first postoperative
day and then advanced to a full liquid diet on the second
postoperative day. Patients were seen in clinic 2 weeks
postoperatively, then every 3 months for the first year. After
the operation, patients received prenatal vitamins, calcium
supplements, vitamin D, and acid suppression medication.
Nutritional supplements were prescribed as needed for
documented deficiencies. All weight measurements were
obtained at the UCSF Bariatric Surgery Center. Calculation
of excess weight loss was based on Metropolitan Life
Insurance height and weight tables to determine ideal body
weight (IBW) [16]. We defined excess weight as the weight
above the patient’s IBW. We calculated the total weight loss
(kg) on each follow-up time and the percent excess weight
loss (%EWL) after surgery, which was weight loss divided
by excess weight multiplied by 100 on each follow-up
point.
Control Group Matching
Controls were matched for gender and the presence of
diabetes. In addition, controls were matched within one
standard deviation for baseline BMI before surgery and for
age. The UCSF Committee on Human Research approved
the protocols, and informed written consent was obtained
from all patients.
Gene Analysis
Genomic DNA was extracted from white blood cells using
standard methods. Our group previously described DNA
sequencing and in vitro analysis of blood samples from
patients with MC4R mutations [7].
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The comparison of %EWL at each follow-up time point (1,
3, 6, 9, and 12 months) between cases (n=4) and matched
controls (n=8) was performed using a paired, two-tailed t
test. Additionally, the comparison between the four cases
and the 88 controls (8 matched controls and 80 non-
matched controls) was performed using linear regression
while adjusting for age, gender, self-reported race, and
baseline BMI.
Results
Identification of MC4R Mutations
Ninety-two patients were screened for MC4R mutations.
The mean ± SD of BMI and age prior to surgery was 55±
8.5 kg/m
2 and 45±10.4 years, respectively.
Four patients carried heterozygous MC4R mutations.
One patient carried the Cys271Phe (812G>T) mutation, one
patient carried the nonsense mutation Gln307stop
(919C>T), and two patients carried the Arg236Cys
(706C>T) mutation. All these mutations cause functional
alteration in vitro [7].
Weight Loss After RYGB
Subjects who were heterozygous for known MC4R non-
synonymous mutations, defined as cases, were matched to
subjects who lacked any non-synonymous MC4R muta-
tions, defined as controls, based on age, sex, BMI, and type
2 diabetes mellitus (see “Patients and Methods”). Four
cases were matched to eight controls (Table 1). We
compared %EWL between MC4R mutation carriers and
the entire cohort of 88 patients without MC4R mutations (4
matched controls and 80 non-matched controls) with a
starting BMI>40 kg/m
2 at all time points (1, 3, 6, 9, and
12 months). There was no statistically significant difference
in %EWL between cases and controls at any time point
(Fig. 1).
Linear regression controlling for age, sex, self-reported
race, and baseline BMI was used to compare %EWL
between cases and all 88 controls patients (8 matched
controls and 80 non-matched controls) without MC4R
mutations in the cohort at the 9- and 12-month follow-up
time points. After controlling for all the above variables,
MC4R mutation carriers did not have a significantly
different %EWL at 9 or 12 months. At 9 months of
follow-up, the mutation carriers had less %EWL compared
to controls; however, at 12 months, the mutation carriers
had more %EWL compared to controls. Thus, neither the
rate nor the absolute amount of weight loss was related
to the presence of MC4R variants. In fact, the only
predictor that was significant was baseline BMI. For
every 10 points greater in BMI, patients lost 10% less
EWL at a follow-up time of 9 months (effect size ± SE,
1±0.38, p=0.006) and 7% less EWL at a follow-up time
of 12 months (effect size ± SE, −0.7±0.3, p=0.026). The
combination of analysis of matched pairs and linear
Table 1 Clinical data from patients heterozygous for MC4R mutations and eight matched non-carrier for MC4R mutations controls
Pair MC4R mutation Gender Age (years) BMI (kg/m
2) Dyslipidemia DM HTN Perioperative
complications
Pair 1
Carrier Cys271Phe Female 55 53.8 − + + None
Control Female 65 55.7 + + + None
Control Female 55 51.2 + + − None
Control Female 55 68.8 − + + None
Pair 2
Carrier Glu307Stop Male 43 54.3 + −− None
Control Male 42 57.9 −− − None
Control Male 49 47.5 −− + None
Pair 3
Carrier Arg236Cys Female 47 63.9 −− − None
Control Female 55 57.3 −− − None
Control Female 49 65.7 −− + None
Pair 4
Carrier Arg236Cys Male 37 43.5 −− − Pneumonia
Control Male 36 40.5 −− + None
DM diabetes mellitus, HTN hypertension, + presence of comorbidity, − absence of comorbidity
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the available cohort.
Perioperative (30 Days) Complications
Among the MC4R mutation carriers, one patient had
aspiration pneumonia and was admitted to the ICU. He
was discharged home on postoperative day 8. Out of
eight matched control patients, none had perioperative
complications.
Discussion
Bariatric surgery is an effective weight loss tool for selected
severely obese patients for whom conventional medical and
behavioral therapy for obesity has failed. With rising
obesity rates, bariatric surgery has become a more common
tool to achieve weight control and resolution of comorbid-
ities [17]. Heterozygous MC4R mutations are the most
common genetic form of obesity, and mutations in this gene
account for approximately 2.5% of severely obese individ-
uals [6, 7]. Our study is the first one to document weight
loss after RYGB in patients with heterozygous MC4R
mutations, and the results, although preliminary, suggest
that patients with these mutations were able to lose as much
weight as patients without MC4R mutations after RYGB. It
is well established that obese patients can achieve a %EWL
of approximately 60% after RYGB [18], and previous
studies suggests that the %EWL after RYGB is superior
than that obtained with gastric banding [19].
A previous report suggested that carriers of genetic
variations at the MC4R locus have poorer outcomes after
gastric banding [2]. This study, however, grouped many
disparate mutations and polymorphisms together. A large
majority of patients in the study carried MC4R variants that
were not associated with obesity (i.e., found also in non-
obese controls) and with no demonstrated functional effect
on the MC4R protein. In addition, patients with binge
eating disorders were included, which has been implicated
in poorer outcomes after bariatric surgery, making the
independent effect of MC4R gene variants in the previous
study unclear [12].
Other studies have demonstrated resolution of or marked
improvement in type 2 diabetes mellitus (DM) after
bariatric surgery [20]. Only one out of the four patients
with MC4R mutations had type 2 DM prior to RYGB,
which did not resolve after surgery. Due to the small
sample size of MC4R mutation carriers, we could not
draw conclusions about the benefits of bariatric surgery
for the resolution of diabetes in patients with heterozygous
MC4R mutations. In a previous cohort of 769 obese adult
patients, there was no significant difference in the
prevalence of type 2 DM between carriers and non-
carriers of MC4R patients. Nineteen patients were found
to be MC4R carriers, and the prevalence of type 2 DM
was 20% among these patients, similar to our patients with
MC4R mutations [6].
The limitations of our study are mostly due to the
rarity of patients with MC4R mutations and the lack of
power to drawn definitive conclusions. Further research
to understand the pathogenic mechanisms underlying
obesity caused by MC4R mutations is required for the
development of rational and effective treatments. This
research is challenging because in addition to the relative
small number of patients with MC4R mutations, there is
great genetic heterogeneity of the disorder. However, our
study is the first one to document weight loss after
RYGB in patients with heterozygous MC4R mutations
and provide preliminary information of outcomes after
RYGB.
In conclusion, and in view of the limitations described
above, our study shows that patients with heterozygous
MC4R mutations had a similar rate of weight loss and %
EWL after RYGB as patients without MC4R mutations.
This suggests that heterozygous MC4R mutation status
should not influence the decision to perform RYGB as a
treatment for severe obesity.
Fig. 1 %EWL curves of MC4R
mutation carriers (n=4),
matched controls for gender,
age, race, BMI, and presence of
diabetes (n=8) and non-matched
controls (n=80) from 1 to
12 months post-RYGB
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